• Title/Summary/Keyword: Adverse Drug Event surveillance system

Search Result 7, Processing Time 0.021 seconds

Development of Mining model through reproducibility assessment in Adverse drug event surveillance system (약물부작용감시시스템에서 재현성 평가를 통한 마이닝 모델 개발)

  • Lee, Young-Ho;Yoon, Young-Mi;Lee, Byung-Mun;Hwang, Hee-Joung;Kang, Un-Gu
    • Journal of the Korea Society of Computer and Information
    • /
    • v.14 no.3
    • /
    • pp.183-192
    • /
    • 2009
  • ADESS(Adverse drug event surveillance system) is the system which distinguishes adverse drug events using adverse drug signals. This system shows superior effectiveness in adverse drug surveillance than current methods such as volunteer reporting or char review. In this study, we built clinical data mart(CDM) for the development of ADESS. This CDM could obtain data reliability by applying data quality management and the most suitable clustering number(n=4) was gained through the reproducibility assessment in unsupervised learning techniques of knowledge discovery. As the result of analysis, by applying the clustering number(N=4) K-means, Kohonen, and two-step clustering models were produced and we confirmed that the K-means algorithm makes the most closest clustering to the result of adverse drug events.

The Comparative Study on Post-Marketing Surveillance System for Pharmaceuticals (의약품의 시판후 조사제도 비교연구)

  • Kim, In-Beom;Kim, Hong-Jin;Sohn, Uy-Dong
    • YAKHAK HOEJI
    • /
    • v.50 no.3
    • /
    • pp.145-153
    • /
    • 2006
  • The adverse events which do not appear in the approval process tend to occur more frequently at the early stage of the use. Therefore new drugs, drugs with different active substances or routes of administration, or drugs with explicitly different efficacy added are particularly chosen for re-examination, and go through a study, which is conducted on 600 to 3,000 subjects over 4 to 6 years. Since the re-examination system was implemented in January 1995, 880 drug products have been designated as the subject of re-examination and among them 194 drugs have been completed their re-examination as of until March 2005. Post Marketing Surveillance to insure drug safety should be correlated with re-examination of new drug, re-evaluation of drug, and adverse event monitoring system. And the first labeling change should reflect all information collected for a defined period of time after the marketing authorization is granted. Furthermore centralized management through spontaneous reporting system of adverse event for whole period of time would be the most desirable type of system.

Identifying the Patterns of Adverse Drug Responses of Cetuximab

  • Park, Ji Hyun
    • Korean Journal of Clinical Pharmacy
    • /
    • v.32 no.3
    • /
    • pp.226-237
    • /
    • 2022
  • Background: Monoclonal antibodies for the treatment of patients with different types of cancer, such as cetuximab, have been widely used for the past 10 years in oncology. Although drug information package insert contains some representative adverse events which were observed in the clinical trials for drug approval, the overall adverse event patterns on the real-world cetuximab use were less investigated. Also, there have been no published papers that deal with the full spectrums of adverse drug events of cetuximab using national-wide drug safety surveillance systems. Methods: In this study, we detected new adverse event signals of cetuximab in the Korea Adverse Event Reporting System (KAERS) by utilizing proportional reporting ratios, reporting odds ratios, and information components indices. Results: The KAERS database included 869,819 spontaneous adverse event reports, among which 2,116 reports contained cetuximab. We compared the labels of cetuximab among the United States, European Union, Australia, Japan, and Korea to compare the current labeling information and newly detected signals of our study. Some of the signals including hyperkeratosis, tenesmus, folliculitis, esophagitis, neuralgia, disseminated intravascular coagulopathy, and skin/throat tightness were not labeled in the five countries. Conclusion: We identified new signals that were not known at the time of market approval.

Development of Adverse Drug Event Surveillance System using BI Technology (BI기술을 적용한 약물부작용감시시스템 개발)

  • Lee, Young-Ho;Kang, Un-Gu;Park, Rae-Woong
    • The Journal of the Korea Contents Association
    • /
    • v.9 no.2
    • /
    • pp.106-114
    • /
    • 2009
  • In this study, we are analysing adverse drug events and proposing a technical structure of "adverse drug event surveillance system" using business intelligence technology, hoping that we can use the system commonly and actively. It is the recent trend to adopt both of electronic review and manual review process to surveil adverse drug events and this study construct CDW applying ETL in BI Technology. As the result of analysis, the data pool included 701 doctors who prescribed and 3059 patients(1528 male, 1531 female), of total 318,222 cases, 2,086cases(0.6%) were suspected as having adverse drug events. And the single type of T.bilirubin> 3mg/dL(ADE type-LabR0005) was the most common(548 among 2085 cases) within the framework of signals.

Adverse Drug Event Surveillance System using Electronic Data and the Signals (전산 데이타를 활용한 약물이상반응검토 및 시그널)

  • Kim, Eun-Young;Kang, Won-Ku;Kwon, Kwang-Il
    • Korean Journal of Clinical Pharmacy
    • /
    • v.21 no.4
    • /
    • pp.383-389
    • /
    • 2011
  • CSS for identifying ADEs are sufficiently developed for broad use and they are much more accurate than spontaneous reporting and more time- and cost-effective than manual chart review. Also computer alert systems can be used to identify opportunities to prevent or reduce patient injury associated with a broad range of ADEs. This CSS can be used to identify opportunities to prevent or reduce patient injury associated with preventable ADEs and increase patient safety, increase quality of drug therapy and decrease the extra-cost of the treatment for ADEs. In the future, increasing utilization of this concurrent CSS should have an enormous beneficial impact on the quality of medical care.

Analysis of Herbal-drug-associated Adverse Drug Reactions Using Data from Spontaneous Reporting System in Electronic Medical Records (EMR의 자발적 약물부작용보고 시스템을 이용한 한약약물유해반응 분석)

  • Kim, Mikyung;Han, Chang-Ho
    • The Journal of Korean Medicine
    • /
    • v.36 no.1
    • /
    • pp.45-60
    • /
    • 2015
  • Objectives: The purpose of this study was to understand the status of reporting and characteristics of adverse drug reactions (ADRs) induced by herbal drugs and to make a suggestion for the domestic pharmacovigilance system on herbal medicine. Methods: We carried out a hospital-based observational study at Dongguk University Ilsan Oriental Hospital from April 2012 to December 2014. We reviewed all the herbal-drug-associated ADRs reports registered to the spontaneous ADR reporting system in electronic medical records of the hospital in the period. Results: We found out 101 reports including 163 herbal-drug-associated ADRs from 97 patients. Females (69.3%) outnumbered males and the most frequent age group was the 50s (44, 27.0%). No serious adverse event was observed. The most commonly reported ADR was gastro-intestinal system disorders (68, 41.5%) followed by skin-related disorders (42, 25.8%). Diarrhea (29, 17.8%) was the most frequently referred clinical manifestation. Most ADRs were induced by internal medicines (160, 98.2%) including manufactured (36, 22.1%) and self-prepared decoction (160, 76.1%). The pairs of Igi-hwan-diarrhea, gamiboa-tang-vomiting, and Magnoliae Flos-gastro-intestinal-system-related ADRs were observed twice each and the others appeared only once. Conclusions: We propose Korean government to take an initiative in national pharmacovigilance system for herbal medicine. To perform the surveillance on herbal drugs, the Association of Korean Medicine (AKOM) should set up a nationwide network by designating centers connecting the Korean medical hospitals, local Korean medicine clinics, and the public health centers. The government and AKOM should also educate and encourage them to understand the pharmacovigilance system and report the ADRs actively.